“Roche is the largest pharmaceutical company by sales in Europe and the third largest in the world. Headquartered in Switzerland, the company has a diverse portfolio of innovative and life-changing medicines that treat a range of debilitating ailments from various forms of cancer to rheumatoid arthritis and multiple sclerosis.
One example is Ocrevus (10% of 2022 group sales), the most popular drug for treating Multiple Sclerosis (MS) in the world. It was first approved in 2017 and since then has significantly helped slow the progression of MS symptoms for hundreds of thousands of patients globally (there are 2.8 million people suffering from the disease worldwide).”
Read the full Money Magazine August stock in focus from our Co-CIO Chad Padowitz below.
You may also be interested in reading…
Contact Us
Find out more by getting in touch with a member of our team
Melbourne
